We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Swiss drugmaker Roche recently announced it has received two positive opinions from the European Medicines Agency Committee for Medicinal Products for Human Use.
Chugai Pharmaceutical has announced that Japan's Intellectual Property High Court ruled in favor of Chugai in a patent infringement suit and a patent invalidation suit involving Ajinomoto, another Japanese pharmaceutical company.
A research center in Uganda will receive more funding to conduct microbicide clinical trials thanks to a multiyear, multimillion-dollar grant from the U.S. NIH.
Emergent BioSolutions announced it has delivered nearly 1 million doses of BioThrax, the only FDA-approved anthrax vaccine, to HHS for placement into the U.S. strategic national stockpile.
Generic drug firms operating in the European Union (EU) should work closely with state agencies to mitigate drug approval delays caused by bureaucratic overload, the European Generic medicines Association (EGA) said at an industry conference.
The Pharmacists' Division of the Association of Professional Engineers, Scientists & Managers, Australia, is calling for the immediate withdrawal of products containing pseudoephedrine from pharmacies.
Israeli drugmaker Teva Pharmaceutical Industries announced that the U.S. FDA has granted final approval to its abbreviated new drug application (ANDA) for rabeprazole sodium delayed-release tablets, 20 mg.
The FDA has issued letters to manufacturers of all attention-deficit/hyperactivity disorder (ADHD) products asking them to implement new medication guides, saying it is concerned about cardiovascular risks and adverse psychiatric symptoms.